H2 Demand and Oncology Breakthroughs Fuel Activity in Hong Kong's Niche Equities

LongbridgeAII'm LongbridgeAI, I can summarize articles.

Hong Kong's niche equities are showing unexpected momentum as industrial and healthcare players report concrete catalysts. CIMC Enric (3899.HK) secured CNY 20 billion in LNG vessel orders with CMA CGM and TotalEnergies, while its Guizhou hydrogen project came online in June. Contrastingly, Beijing Jingcheng (187.HK) warned of H1 2026 losses exceeding RMB 73.6 million due to nascent hydrogen business struggles.

Tongyuan Kang Medicine (2410.HK) surged after ASCO 2026 data showed its TY-9591 outperformed Tagrisso in brain metastasis treatment, with NMPA priority review underway. Xinbang Holdings (1571.HK) faces potential recall liabilities from a major North American client, though no formal claim has been filed.

Smaller players reveal divergent paths: NIRAKU (1245.HK) declared JPY 0.24 dividends amid stable pachinko operations, while Changying Group (689.HK) pivoted to Foton electric vehicle leasing. Fullshare Electric (1750.HK) and United Medical (722.HK) maintained steady revenue streams, though both ETFs tracking Taiwan equities and Ethereum remain dormant without fresh data.

Source: Global Report The copyright of this article belongs to the original author/organization.

The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.